May 14, 2020
Applied DNA Reports 2020 Fiscal Second Quarter Financial Results
Company to Hold Conference Call and Webcast Today, Thursday, May 14, 2020, at 4:30 p.m. EDT STONY BROOK, N.Y.–(BUSINESS WIRE)–$APDN…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
May 14, 2020
TFF Pharmaceuticals Reports First Quarter 2020 Financial and Business Results
Maintains clinical progress with lead programs, Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder Thin Film Freezing platform technology employed in…
May 14, 2020
Aurinia Reports First Quarter 2020 Financial Results and Recent Operational Highlights
– Cash and cash equivalents totaled approximately $286 million at March 31, 2020 – – Rolling submission of voclosporin New…
May 14, 2020
Alpine Immune Sciences Reports First Quarter 2020 Financial Results and Provides Company Update
– Granted FDA Orphan Drug Designations for ALPN-101 in Acute GVHD – – BALANCE and NEON-1 Trials Open for Enrollment…
May 14, 2020
Pfizer’s 20vPnC vaccine candidate meets primary immunogenicity
Pfizer’s 20vPnC vaccine candidate in Pahse 3 study showed responses elicited by 20vPnC for all 20 serotypes equivalent across all three lots, meeting the primary immunogenicity objective of the study.
May 14, 2020
Boehringer Ingelheim expands immuno-oncology portfolio with Northern Biologics’ preclinical cancer antibody pipeline
Boehringer Ingelheim has bought Northern Biologics Inc., a wholly owned subsidiary of Northern LP, whose programs targeting the tumor microenvironment are the latest in a series of strategic acquisitions and collaborations that strengthen Boehringer Ingelheim’s position in cancer immunology,
May 14, 2020
Medicago’s vaccine candidate against COVID-19 induces positive results in animal trials
Medicago, a biopharmaceutical company headquartered in Quebec City, announced today that its vaccine candidate for COVID-19 induced a positive antibody response only 10 days after a single dose in mice.
May 14, 2020
LG Chem Life Sciences Innovation Center Announces Data from Phase I Study of its Ulcerative Colitis Treatment LC51-0255
–Positive Topline Results of Oral LC51-0255 Presented at Virtual Digestive Disease Week (DDW) 2020 as ePoster CAMBRIDGE, Mass.–(BUSINESS WIRE)–#S1P1–LG Chem…
May 14, 2020
BIO Appoints a Physician-Scientist as New President and CEO
Immunologist Michelle McMurry-Heath is Selected for Her Global Leadership and Commitment to Innovation and Patients Former FDA Official Will Succeed…
May 14, 2020
X4 Pharmaceuticals Announces Data from Phase 2 Open-Label Extension Trial of Mavorixafor in WHIM Syndrome as Published in EHA Abstract
Data reveal reductions in annual infections and warts, and sustained dose-dependent increases in neutrophil counts These and additional Phase 2…